erlotinib hydrochloride has been researched along with Respiratory Tract Infections in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Castillo, P; González-Sánchez, N; Grau, JJ; Haag, O; Remacha, J; Rojas-Lechuga, MJ; Vilaseca, I | 1 |
| Hsu, JH; Li, MF; Shiau, EL; Wu, MT | 1 |
| Biddinger, P; Dillard, T; Hao, Z; Patel, V | 1 |
3 other study(ies) available for erlotinib hydrochloride and Respiratory Tract Infections
| Article | Year |
|---|---|
Juvenile recurrent respiratory papillomatosis treated with combined erlotinib and celecoxib: Initial report.
Topics: Adolescent; Antineoplastic Agents; Celecoxib; Child; Child, Preschool; Combined Modality Therapy; Cyclooxygenase 2 Inhibitors; Erlotinib Hydrochloride; Female; Humans; Papillomavirus Infections; Respiratory Tract Infections; Retreatment; Young Adult | 2020 |
Recurrent respiratory papillomatosis with lung involvement and malignant transformation.
Topics: Bronchial Neoplasms; Bronchoscopy; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Chemoradiotherapy, Adjuvant; Contrast Media; Disease Progression; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Papillomavirus Infections; Protein Kinase Inhibitors; Quinazolines; Respiratory Tract Infections; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Suppression of respiratory papillomatosis with malignant transformation by erlotinib in a kidney transplant recipient.
Topics: Bronchoscopy; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Erlotinib Hydrochloride; Humans; Kidney Transplantation; Lung Neoplasms; Male; Middle Aged; Papillomavirus Infections; Protein Kinase Inhibitors; Quinazolines; Respiratory Tract Infections; Thoracic Surgery, Video-Assisted | 2013 |